Videos

John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.

Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.

Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.

Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.

Neeta Somaiah, MD, discusses the evolution of treatment options for patients with a unique sarcoma.

Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.

Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.

Felix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.

Corey S. Cutler, MD, MPH, discusses the current treatment options for patients with chronic graft-versus-host-disease and highlighted some upcoming research.

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.